Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation (Summary of Impact of Error on Condensed Consolidated Balance Sheets) (Details)

v3.24.1
Basis of Presentation (Summary of Impact of Error on Condensed Consolidated Balance Sheets) (Details) - USD ($)
Dec. 31, 2023
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Assets        
Prepaid research and development costs $ 1,228,509 $ 1,006,252 $ 7,908,118  
Total current assets 53,344,667 22,933,222 70,499,829  
Total assets 80,566,885 50,023,091 101,273,636  
Liabilities and Stockholders' Equity        
Accrued research and development costs     10,077,457  
Total current liabilities 16,624,753 17,810,732 37,479,728  
Total liabilities 28,964,613 30,344,930 52,082,875  
Accumulated deficit (265,044,190) (256,768,209) (202,324,474)  
Total stockholders' equity 51,602,272 19,678,161 49,190,761 $ 82,797,317
Total liabilities and stockholders' equity $ 80,566,885 $ 50,023,091 101,273,636  
As Reported [Member]        
Assets        
Prepaid research and development costs     10,416,934  
Total current assets     73,008,645  
Total assets     103,782,452  
Liabilities and Stockholders' Equity        
Accrued research and development costs     12,678,176  
Total current liabilities     40,080,447  
Total liabilities     54,683,594  
Accumulated deficit     (202,416,377)  
Total stockholders' equity     49,098,858  
Total liabilities and stockholders' equity     103,782,452  
Adjustment [Member]        
Assets        
Prepaid research and development costs     (2,508,816)  
Total current assets     (2,508,816)  
Total assets     (2,508,816)  
Liabilities and Stockholders' Equity        
Accrued research and development costs     (2,600,719)  
Total current liabilities     (2,600,719)  
Total liabilities     (2,600,719)  
Accumulated deficit     91,903  
Total stockholders' equity     91,903  
Total liabilities and stockholders' equity     $ (2,508,816)